替尔泊肽在代谢疾病中的研究进展
Research Progress of Tirzepatide in Metabolic Diseases
DOI: 10.12677/acm.2026.1672603, PDF,   
作者: 孙 昊：北华大学临床医学院，吉林 吉林；孙昕昳*：北华大学附属医院全科医学科，吉林 吉林
关键词: 替尔泊肽；代谢性疾病；研究进展；GIP/GLP-1双受体激动剂；Tirzepatide； Metabolic Diseases； Research Progress； GIP/GLP-1 Dual Receptor Agonist
摘要: 当前全球代谢性疾病发病率持续攀升，传统降糖、调脂类药物多为单一靶点干预，难以同步改善糖脂紊乱、体重异常等多重问题。替尔泊肽作为首个获批的GIP/GLP‑1双受体激动剂，依托胰高糖素样肽‑1 (GLP‑1)受体与葡萄糖依赖性促胰岛素多肽(GIP)受体的协同激活效应，在代谢性疾病治疗中展现出多方面作用。近年来多项临床研究结果显示，其在2型糖尿病、肥胖症、代谢相关脂肪性肝病、阻塞性睡眠呼吸暂停等代谢相关疾病中，可实现降糖、减重、改善胰岛素抵抗、调节脂代谢以及抑制慢性炎症等多重效果。本文系统梳理替尔泊肽的作用机制与临床研究进展，总结代谢疾病领域探索方向，为临床合理应用提供参考。
Abstract: The global incidence of metabolic diseases continues to rise. Traditional antidiabetic and lipid-modulating drugs typically target a single pathway, making it difficult to simultaneously address multiple issues such as glucose-lipid disorders and abnormal body weight. Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, exerts broad therapeutic effects in metabolic diseases through the synergistic activation of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Recent clinical studies have shown that tirzepatide can effectively lower blood glucose, promote weight loss, improve insulin resistance, regulate lipid metabolism, and suppress chronic inflammation in conditions including type 2 diabetes, obesity, metabolic-associated fatty liver disease, and obstructive sleep apnea. This article systematically reviews the mechanism of action and clinical research progress of tirzepatide, summarizes key directions in metabolic disease research, and provides insights for its rational clinical application.
文章引用：孙昊, 孙昕昳. 替尔泊肽在代谢疾病中的研究进展[J]. 临床医学进展, 2026, 16(7): 935-942. https://doi.org/10.12677/acm.2026.1672603

参考文献

[1] Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., Vollset, S.E., Smith, A.E., et al. (2023) Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 402, 203-234. [Google Scholar] [CrossRef] [PubMed]
[2] Magliano, D.J. and Boyko, E.J. (2021) IDF Diabetes Atlas. 10th Edition, International Diabetes Federation.
[3] Smyth, S. and Heron, A. (2006) Diabetes and Obesity: The Twin Epidemics. Nature Medicine, 12, 75-80. [Google Scholar] [CrossRef] [PubMed]
[4] ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Ekhlaspour, L., et al. (2023) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47, S158-S178. [Google Scholar] [CrossRef] [PubMed]
[5] Nauck, M.A. and Meier, J.J. (2019) GIP and GLP-1: Stepsiblings Rather than Monozygotic Twins within the Incretin Family. Diabetes, 68, 897-900. [Google Scholar] [CrossRef] [PubMed]
[6] Frías, J.P., Davies, M.J., Rosenstock, J., Pérez Manghi, F.C., Fernández Landó, L., Bergman, B.K., et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385, 503-515. [Google Scholar] [CrossRef] [PubMed]
[7] Rosenstock, J., Wysham, C., Frías, J.P., Kaneko, S., Lee, C.J., Fernández Landó, L., et al. (2021) Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet, 398, 143-155. [Google Scholar] [CrossRef] [PubMed]
[8] Coskun, T., Sloop, K.W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K.B., et al. (2018) LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. Molecular Metabolism, 18, 3-14. [Google Scholar] [CrossRef] [PubMed]
[9] Vogt, É.L. and Kowaltowski, A.J. (2026) GLP-1, Pancreatic β-Cells, and Insulin Secretion: What We Know and Where We Need to Go. Diabetes, 75, 403-413. [Google Scholar] [CrossRef] 
[10] Widenmaier, S.B., Kim, S.J., Yang, G.K., De Los Reyes, T., Nian, C., Asadi, A., et al. (2010) A GIP Receptor agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control. PLOS ONE, 5, e9590. [Google Scholar] [CrossRef] [PubMed]
[11] Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J.J. and Bülow, J. (2010) Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-Esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. Diabetes, 59, 2160-2163. [Google Scholar] [CrossRef] [PubMed]
[12] Getty‐Kaushik, L., Song, D.H., Boylan, M.O., Corkey, B.E. and Wolfe, M.M. (2006) Glucose‐Dependent Insulinotropic Polypeptide Modulates Adipocyte Lipolysis and Reesterification. Obesity, 14, 1124-1131. [Google Scholar] [CrossRef] [PubMed]
[13] Guo, L., Dong, X., Ma, J., Liu, M., Lu, Y., Wang, H., et al. (2024) Efficacy and Safety of Tirzepatide Added to Basal Insulin in Patients with Type 2 Diabetes in China (SURPASS-CN-INS): A Double-Blind, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Diabetes & Endocrinology, 13, 1015-1029. [Google Scholar] [CrossRef] 
[14] Kiyosue, A., Dunn, J.P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., et al. (2023) Safety and Efficacy Analyses across Age and Body Mass Index Subgroups in East Asian Participants with Type 2 Diabetes in the Phase 3 Tirzepatide Studies (SURPASS Programme). Diabetes, Obesity and Metabolism, 25, 1056-1067. [Google Scholar] [CrossRef] [PubMed]
[15] Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216. [Google Scholar] [CrossRef] [PubMed]
[16] Garvey, W.T., Frias, J.P., Jastreboff, A.M., le Roux, C.W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N.N., Bunck, M.C., Benabbad, I. and Zhang, X.M. (2023) Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 402, 613-626.
[17] Zhao, L., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., et al. (2024) Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA, 332, 551-560. [Google Scholar] [CrossRef] [PubMed]
[18] Gourgari, E., Srivastava, G., Kelly, A.S., Mojdami, D., Cao, D., Murphy, M.A., et al. (2025) Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the surmount Clinical Trials. Obesity, 33, 1668-1679. [Google Scholar] [CrossRef] [PubMed]
[19] Del Prato, S., Kahn, S.E., Pavo, I., Weerakkody, G.J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A.G., et al. (2021) Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardio-Vascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial. The Lancet, 398, 1811-1824.
[20] Nicholls, S.J., Pavo, I., Bhatt, D.L., Buse, J.B., Del Prato, S., Kahn, S.E., et al. (2025) Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393, 2409-2420. [Google Scholar] [CrossRef] 
[21] Loomba, R., Hartman, M.L., Lawitz, E.J., Vuppalanchi, R., Boursier, J., Bugianesi, E., et al. (2024) Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine, 391, 299-310. [Google Scholar] [CrossRef] [PubMed]
[22] Malhotra, A., Grunstein, R.R., Fietze, I., Weaver, T.E., Redline, S., Azarbarzin, A., et al. (2024) Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, 391, 1193-1205. [Google Scholar] [CrossRef] [PubMed]
[23] Noreña, J.A., Akcan, T. and Desai, D. (2026) Beyond Weight Loss: Tirzepatide as a Dual GIP/GLP-1 Receptor agonist for Obstructive Sleep Apnea. Current Opinion in Endocrinology, Diabetes & Obesity, 33, 108-114. [Google Scholar] [CrossRef] 
[24] Packer, M., Zile, M.R., Kramer, C.M., Baum, S.J., Litwin, S.E., Menon, V., et al. (2025) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392, 427-437. [Google Scholar] [CrossRef] [PubMed]
[25] Borlaug, B.A., Zile, M.R., Kramer, C.M., Baum, S.J., Hurt, K., Litwin, S.E., et al. (2025) Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure with Preserved Ejection Fraction and Obesity: A Secondary Analysis of the SUMMIT Trial. Nature Medicine, 31, 544-551. [Google Scholar] [CrossRef] [PubMed]
[26] Dani, S.S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., et al. (2025) An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists. JACC: Advances, 4, Article 101740. [Google Scholar] [CrossRef] [PubMed]

为你推荐